Adalimumab to guselkumab
There was no adalimumab continuation arm. In patients who switched from adalimumab to guselkumab at week 28, NAPSI and f-PGA improved from week 24 to week 48; mean NAPSI 2.2 vs 1.5; mean f-PGA 1.2 vs 0.9, respectively. Improvements were also observed in PASI and DLQI; mean PASI 7.1 vs 1.8 and mean DLQI 8.0 vs 2.90, respectively (Fig. 